header people places

Jeff Greene’s landmarked Post Office in Palm Beach, once the island’s main post office, was the historic venue for a Civic Association reception for Scripps Florida.

Bob Wright, Chairman of the Civic Association, shared opening remarks and introduced Mr. Greene and Peter Schultz, CEO of Scripps Research Institute.  Mr. Wright descibed Scripps as a cutting-edge organization for scientific discoveries that will translate into new medicines for humanity.

Photo: Dr. Peter Schultz, Bob Wright, Alex Dreyfoos, Jeff Greene

Mr. Greene told the 60 plus attendees how his family had a small apartment nearby when he was young, and he collected mail for his father from a P.O. Box here. He even remembered the number. In 2011, Mr. Greene paid a recorded $3.7 million for the 1936 landmarked building, which now houses offices for his Florida Sunshine Investments.

Mr. Wright then introduced Dr. Schultz, Scripps CEO, who outlined the following new active discoveries they are working on:

“We have royalty income that we've analyzed -- from not one, but four drugs. We're talking to various groups about monetizing that. There are antibiotics, cardiovascular drugs, and there are autoimmune drugs.”

“With the Gates Foundation, we have a molecule for tuberculosis and one for childhood diarrhea, going into the clinic in the first quarter this year. We started the Gates collaboration two and a half years ago.”

“We have a chemical vaccine against malaria, and we have novel antivirals that target not only Ebola but also Marburg and we also have a novel strategy for Zika. That’s just with the Gates Foundation.”

“We’re just finishing toxicology studies with a regenerative medicine for osteoarthritis that the California Institute for Regenerative Medicine wants to fund. That’ll be dosed in patients probably in the first quarter of this year.”

“We have one for chronic heart failure we’ve partnered with pharma. And in that case, the pharma asked us to do the Phase 1 trial.”

“We have a molecule for childhood diabetes, which is liver-targeted insulin. And we have molecule that could actually change the way we treat autoimmune disease.”

The interested group was happy to hear from Dr. Schultz that Scripps Florida would be here for the long term.  He said the campus is the “fourth-highest recipient of NIH funding in the state of Florida, which isn't bad for a pretty young, small institute.  There's a huge number of really interesting scientific and medical opportunities that have been developed in Scripps Florida.”


2017 Scripps Research Institute Reception - January 31, 2017